The Dexcom G6 is recommended for patients with Type 2 diabetes on insulin using pump therapy or multiple daily insulin injections (MDI).
Vincent V., Age 37
A small wearable continuously sends glucose readings to your smartphone* or Dexcom receiver – without fingersticks.†
† Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
The Dexcom G6 is a small wearable you apply yourself. It lasts up to 10 days and no one even knows you have it on.
Glance at your smartphone*. See your glucose. Make diabetes treatment decisions. All without fingersticks†.
† Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Using a Dexcom CGM is proven to lower A1C and help you spend more time in range.1,2
You can set alerts to notify you when your glucose is heading high or low.
Your biggest questions answered about the Dexcom G6.
A: Yes. Most people who have insulin dependent type 1 and type 2 diabetes, and who are with a major insurance carrier are covered.
In fact, more patients pay out-of-pocket costs for Abbott Freestyle than Dexcom G6 through their pharmacy benefits.††
A: Dexcom G6 is easy for everyone to use.‡ It’s a powerful diabetes management tool that is designed to simply and effectively help you reach your diabetes goals.
A: It’s easy to get started with the Dexcom G6. We’ll give you a free benefits check and walk you through the process.
Dr. Michael Heile, T1D
Endocrinologist
Paid spokesperson of Dexcom, Inc.
† Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
* For a list of compatible devices, visit http://www.Dexcom.com/compatibility.
‡ See user guide for set up instructions
1 Beck, RW. JAMA. 2017; 317(4); 371-378.
2 Welsh, J.B. Diabetes Technol Ther. 2019; 21(3).
§ Based upon a customer's experience; individual results may vary. Randomized controlled trial and real-world data indicate that Dexcom CGM use results in a mean A1C reduction of 0.8%1 and 1.5%,2 respectively, from baseline for patients with T2D.
††Data on File: Source: IQVIA July 2020, Rolling 3 months
BRIEF SAFETY STATEMENT: Available by prescription only. Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www. dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.